Costs of Drug Therapy in Patients with Ankylosing Spondylitis in Brazil

Abstract

IntroductionThe Brazilian Public Health System offers free-of-charge drug treatment for ankylosing spondylitis (AS) to all Brazilian citizens. We report here the first population-based cohort study on patients with AS in Brazil. The aim of this study was to evaluate the costs of the tumour necrosis factor (anti-TNF) blockers and disease-modifying antirheumatic drugs (DMARDs) that were used in the treatments of patients with AS in Brazil between March 2010 and September 2013.MethodsA retrospective cohort study was performed using administrative databases. All patients with a diagnosis of AS who were aged 18 years or older and had been dispensed anti-TNF or DMARDs were included in the analysis. The cost analysis was carried out from the health system perspective, and the results were described as median monthly cost per capita and the annual cost over the study period.ResultsA search of the databases identified 1251 patients with AS who were treated during the study period, of whom 63.3% were male; the median age was 41 years. During the study period, 78.0% of patients initiated treatment with anti-TNF drugs and 22.0% with DMARDs. The median monthly cost per capita was US$ 1650 for anti-TNF therapy and US$ 25 for treatment with DMARDs. Among the anti-TNF drugs, therapy with etanercept was associated with the lowest cost per patient, followed by adalimumab and infliximab. No difference in monthly cost was observed in relation to gender and age.ConclusionThe cost per patient of treating AS in this study cohort was lower with etanercept than with adalimumab and infliximab. These results highlights the economic burden of treating patients with AS.

MEFV M694V mutation has a role in susceptibility to ankylosing spondylitis: A meta-analysis

“…Estimates of the prevalence of ankylosing spondylitis in the United States even reach 0.5% [ 5 ]. Moreover, AS has significant economic implications for individuals and society [ 6 – 8 ]. Therefore, it is urgent to study the pathogenesis and treatment of ankylosing spondylitis.…”

Cost of Illness, Quality of Life, and Work Outcomes in Active Ankylosing Spondylitis Patients Treated With Adalimumab in China

“…AS-related healthcare cost varied in different countries and it is difficult to compare work-related cost beyond the country of origin. In Brazil, a population-based cohort study reported 78% of AS patients initiating treatment with anti-TNF drugs (free of charge) with a median monthly cost per capita of $1650 (21). An UK research reported that the total cost of AS was estimated at e19016 per patient per year and the majority of the cost was a result of work-related costs (7).…”

RUNX3 Polymorphisms Affect the Risk of Ankylosing Spondylitis

“…AS imposes a heavy burden and huge economic loss on patients, families, and society [3]. Although drug treatment has been improved for AS, currently available medicines fail to achieve satisfactory effects [4]. The pathogenesis of AS remains unclear, but it is accepted that disease onset occurs by interactions between environmental and genetic factors [5,6].…”